Posted by AGORACOM-JC
at 9:13 PM on Monday, September 7th, 2020
The Tortoise and the Hare is the famous fable most of us grew up with that teaches this very important lesson – you can be more successful by doing things slowly and steadily than by acting quickly and carelessly. Said another way, slow and steady wins the race.
Avicanna (AVCN:TSX) (AVCNF:OTCQB) (0NN:Frankfurt) is the Hare. The company very few paid attention to because it started off the Cannabis stock market race slowly and surely, while all the other rabbits ran so quickly to win the race that they ended up tripping over themselves or getting so exhausted they couldn’t finish the race.
You know who those companies are. All flash, big promises, big promotions, big stock prices ….. and HUGE disappointments.
Avicanna has surpassed all of them and is starting to pick up speed. When Avicanna says it is vertically integrated, it isn’t a buzz word, it’s the real story with 4 fully operating divisions that are hitting on all cylinders including, Tier-1 National Partnerships, Global Distribution, Medical Acceptance and History Making Sales.
Here is a snapshot of what we are referring to, followed by an incredible interview with CEO, Aras Azadian, whose quiet confidence sends the following powerful message –
“Watch Us Cross The Finish Line”
CONSUMER RETAIL – COSMETICS
The Only Known CBD Cosmetics Backed By Clinical Trials
Full Line Of High End CBD Based Skin Care Products
Already Commercializing In Colombia
Global Distribution In H2 2020 In United States, Europe and Canada
Canadian Distribution Through Shoppers Drug Mart
MEDICAL CANNABIS
Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
Successfully launched advanced products under RHO Phyto™ brand nation-wide in Canada through Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart
Global Distribution Through US, U.K, Australia, Colombia in H2 2020
PHARMACEUTICALS
A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
3 Products Already As Far As PHASE 2
CULTIVATION
500,000 Sq Ft Of Low Cost and USDA certified Organic Cannabis Cultivation In Colombia First Ever Export Of Feminized Hemp Seeds From Colombia (To United States).
7,000,000 Seeds For $380,000Additional 75,000,000 Seeds Available For Export In Several Pending Transactions
Q2 HIGHLIGHTS
Revenue increased 172% from $260,903 in Q1 2020 to $709,468 in Q2 2020, and a substantial increase from $16,571 in Q2 2019, coupled with 8% cost reduction from Q1 2020, and 31% cost reduction from Q2 2019
Posted by AGORACOM-JC
at 8:31 AM on Friday, September 4th, 2020
Company has completed exports of CBD water soluble formula into the United States and CBD-based cosmetics into the United Kingdom
Company is also pleased to announce that the Colombian Ministry of Health has granted SMGH a commercial and industrial fabrication quota to produce psychoactive THC derivatives.
The export and sale of the commercial lot of isolated CBD water soluble formula into the United States was completed in parallel with an export of CBD-based cosmetics into the United Kingdom
The cultivation, extraction and purification of these products were all completed through Avicanna’s vertical integration at SMGH and validate the Company’s innovation and leadership in natural rare cannabinoid production
TORONTO, Sept. 4, 2020 – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces that through its majority owned subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH“), the Company has completed exports of CBD water soluble formula into the United States and CBD-based cosmetics into the United Kingdom. The Company is also pleased to announce that the Colombian Ministry of Health has granted SMGH a commercial and industrial fabrication quota to produce psychoactive THC derivatives.
The Company also announces that it has amended and refiled its interim financial statements for the period ended June 30, 2020 (the “Interim Financial Statements”) which amend the Company’s interim financial statements for the same period originally filed on SEDAR on August 14, 2020. At the request of the Ontario Securities Commission, the Interim Financial Statements have been updated to include comparative financial information for the corresponding interim period in the immediately preceding financial year as such information was inadvertently omitted in the initial filing. The changes are for presentation purposes and no figures have been restated. The Company has updated the Statement of Changes in Equity to include the immediately preceding financial year June 30, 2019 balances as required by Section 4.3(2)(b) of National Instrument 51-102 – Continuous Disclosure Obligations.
The export and sale of the commercial lot of isolated CBD water soluble formula into the United States was completed in parallel with an export of CBD-based cosmetics into the United Kingdom. The cultivation, extraction and purification of these products were all completed through Avicanna’s vertical integration at SMGH and validate the Company’s innovation and leadership in natural rare cannabinoid production. The CBD water soluble formula is part of the Aureus™ product portfolio that now includes feminized seeds and advanced formulations as well as CBD, CBG and THC API products. The CBD-based cosmetics were manufactured using CBD produced by SMGH and formulas developed by Avicanna.
The Colombian Ministry of Health granted SMGH a supplementary fabrication quota to receive 1.4 tons of dry flower and transform them into approximately 150 kg of psychoactive derivatives which will be used for commercial exports.
To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.
About Avicanna
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:
Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.
With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.
Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.
Stay Connected
For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to complete additional exports of CBD water soluble formula to the United States, the ability of the Company to complete additional exports of CBD-based cosmetics in to the United Kingdom, the ability of the Company to continue manufacturing CBD-based cosmetics using CBD produced by SMGH, the ability of SMGH to receive 1.4 tons of dry flower for the purposes of extracting psychoactive derivatives, and the ability of SMGH to produce 150 kg of psychoactive derivatives. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.
The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Posted by AGORACOM-JC
at 8:25 AM on Friday, September 4th, 2020
Kontrol BioCloud is a Safe Space Technology –
Announced that sagecomm, a leading marketing communications firm, has been engaged to share the BioCloud story across the country
sagecomm is a leading strategic marketing and communications firm whose principals have more than 20 years of progressive experience in marketing-communications in both public and private environments, including education, technology, healthcare, banking, non-profit, and government sectors
“Following the completion of several important development milestones we feel the time is appropriate to share our story and our technology development to a larger audience through the media,” says Paul Ghezzi, CEO of Kontrol.
TORONTO, ON / September 4, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that sagecomm, a leading marketing communications firm, has been engaged to share the BioCloud story across the country.
“Following the completion of several important development milestones we feel the time is appropriate to share our story and our technology development to a larger audience through the media,” says Paul Ghezzi, CEO of Kontrol. “We look forward to working with the sagecomm team.”
About sagecomm
sagecomm is a leading strategic marketing and communications firm whose principals have more than 20 years of progressive experience in marketing-communications in both public and private environments, including education, technology, healthcare, banking, non-profit, and government sectors.
“We are impressed with the Kontrol team and excited about the potential of BioCloud and look forward to creating a growing audience for Kontrol,” added Jeff Sage, Co-Founder and Senior Strategist at sagecomm.
About Kontrol BioCloud
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
About Kontrol Energy
Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.
For further information, contact:
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp., 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 10:45 AM on Thursday, September 3rd, 2020
Announced the largest purchase order to date from a Canadian Mining Company with operations worldwide
P.O. is for 50,000 1drop Inc.
P.O. is for their Peru and Surinam mining operations.
Total gross sales amount is approximately $1.6M CAD, excluding shipping and courier fees
COVID-19 test kits manufactured by 1drop Inc.
TORONTO, Sept. 03, 2020 — Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce the largest purchase order (the “P.O.”) to date from a Canadian Mining Company (the “Purchaser”) with operations worldwide. The P.O. is for 50,000 1drop Inc. This P.O. is for their Peru and Surinam mining operations. The total gross sales amount is approximately $1.6M CAD, excluding shipping and courier fees. The P.O. is for 50,000 COVID-19 test kits manufactured by 1drop Inc.
Under the terms of the P.O., Datametrex will provide the Purchaser with an initial 50,000 units of the COVID-19 qPCR Detection Kits manufactured by 1drop Inc. (“1drop”), 50,000 Universal Transport Medium (UTM®), Sterile Swabs with 16x100mm and Skirted Tubes. The Company is also shipping two (2) Real-Time Polymerase Chain Reaction Detection System (“PCR”) machines along with software to ensure optimal assay performance of the samples, and 50,000 RNA extraction kits.
Datametrex anticipates that it has little or no upfront costs associated with the sale of these test kits. All of the items are shipped directly from manufacturers to the purchaser’s mine operating sites in Peru and Surinam.
A publicly available survey provided by Statista with sources from Johns Hopkins University (CSSE), World Bank, and Insee, states that Peru is the most impacted country with the most deaths per million (908.8 deaths per million, at the date of this news release – source: https://bit.ly/3bikTRo). Also, Peru is the number two copper producer in the world and with the mining stoppages from the COVID-19 pandemic, combined with operational issues, mine output has declined by 23% over the first five months, with April and May registering declines of 33% and 41%, respectively, as stated by the International Copper Study Group recently reported – source: https://bit.ly/3i64Qc5
“Datametrex is glad to be able to help companies in Peru deal with this urgent situation. Assisting with the implementation of test kits is a fundamental response to the pandemic, and those mining companies that have been able to test more comprehensively have had greater success dealing with the pandemic,” says Marshall Gunter, CEO of the Company. “The reasoning is simple: An individual who tests positive can be isolated until they recover, and their contacts may be traced and similarly tested and isolated, effectively reducing the rate of transmission. We hope our technologies, combined with everyone’s efforts, contribute to the mitigation of the spread in operational mining sites.”
About Datametrex
Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.
Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 8:45 AM on Thursday, September 3rd, 2020
The global online gambling market could potentially hit $1 TRILLION by the end of this decade. That isn’t a typo and the reasons are pretty clear – more jurisdictions are legalizing online gambling to get their hands on the tax revenue and the remaining 40% of people on the planet without internet access are going to get it.
Until recently, however, small-cap investors did not have a company that could provide them ground floor exposure to this massive market and its growth over the next 10 years. The industry was dominated by the big traditional gambling companies, who focus heavily on old fashioned gambling.
That all changes with FansUnite, the small cap iGaming super company that goes beyond simple gambling and attacks both sides of the iGaming market by offering both B2C and B2B gambling platforms.
$5,000,000 Financing In Support Of The Acquisition
World Renowned Team
…. And now FANS just entered the US market in record time thanks to a partnership that saved them 12-24 months and millions and millions of dollars.
If you are looking for a disruptive technology company that is well positioned to carve out its share of the massive online gambling world, then you need to watch or listen to our interview with FANS CEO, Scott Burton.
Posted by AGORACOM-JC
at 8:22 AM on Thursday, September 3rd, 2020
Kontrol BioCloud a Safe Space Technology™
During the week of August 31, 2020 Kontrol continued lab testing on its fully operating prototype to validate certain components required for commercialization of BioCloud
The testing continues to demonstrate positive results as previously reported in the press release dated August 27, 2020.
live COVID-19 testing has been rescheduled to the week of September 8th in order to secure ample time slots in the independent lab
To align with the completion of COVID-19 live testing, Kontrol anticipates having 5 functioning BioCloud units that can operate in real-time in the coming weeks
TORONTO, ON / September 3, 2020 / Kontrol Energy Corp.(CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to provide an update on its Kontrol BioCloud (or “BioCloud“) technology.
Lab Testing with Prototype and Dormant COVID
During the week of August 31, 2020 Kontrol continued lab testing on its fully operating prototype to validate certain components required for commercialization of BioCloud. The testing continues to demonstrate positive results as previously reported in the press release dated August 27, 2020.
“Through additional testing we are in a position where we can determine that our detection chamber and fully operational prototype continue to deliver positive results against COVID-19 in its dormant form,” says Paul Ghezzi, CEO Kontrol. “In addition, we have enhanced supply chain certainty over all material components required for commercialization.”
Live COVID-19 Testing
The live COVID-19 testing has been rescheduled to the week of September 8th in order to secure ample time slots in the independent lab.
Prototypes and Function Units
To align with the completion of COVID-19 live testing, Kontrol anticipates having 5 functioning BioCloud units that can operate in real-time in the coming weeks.
About Kontrol BioCloud
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
About Kontrol Energy
Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.
For further information, contact:
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp., 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 7:17 AM on Thursday, September 3rd, 2020
Mackie Research’s analyst, Yue (Toby) Ma, Ph.D., indicates in the updated Enterprise report that Innocan’s potential catalysts are:
Clinical Catalyst: Pre-clinical data of CLX in COVID-19 is expected in 9 to 12 months.
Licensing Catalyst: Innocan is looking to out-license CLX and the liposome product before Phase 1 trials.
Commercial Catalyst: Innocan’s CBD-based consumer health products are expected to be launched in several international markets in Q4 2020. The company is looking to sign more regional distribution agreements going forward.
Herzliya, Israel and Calgary, Alberta–(September 3, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that Mackie Research Capital Corporation’s institutional sales group has issued an updated Enterprise report on the Company.
The Enterprise report provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into action.
Mackie Research’s analyst, Yue (Toby) Ma, Ph.D., indicates in the updated Enterprise report that Innocan’s potential catalysts are:
Clinical Catalyst: Pre-clinical data of CLX in COVID-19 is expected in 9 to 12 months.
Licensing Catalyst: Innocan is looking to out-license CLX and the liposome product before Phase 1 trials.
Commercial Catalyst: Innocan’s CBD-based consumer health products are expected to be launched in several international markets in Q4 2020. The company is looking to sign more regional distribution agreements going forward.
This Enterprise report is based upon general comments with no ratings and should not be construed to be a research report.
About Innocan
The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The Company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of InnoCan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
For further information, please contact:
For Innocan Pharma Corporation: Iris Bincovich, CEO +972-54-3012842 [email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond InnoCan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by InnoCan, including expectations and assumptions concerning the anticipated benefits of the product, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact InnoCan can also be found in InnoCan’s public reports and filings which are available under InnoCan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. InnoCan Pharma does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Posted by AGORACOM-JC
at 11:04 AM on Wednesday, September 2nd, 2020
Hilaria Baldwin Chooses Else Nutrition on E! Daily Pop
https://youtu.be/UBiYSt9Jekg
“As many of you know, my family primarily eats a dairy-free, plant-based diet. I nurse my babies and am always looking for a plant-based toddler formula to transition to once they are weaned. There hasn’t been anything on the market except soy until now. This is why I’m so excited to share @elsenutrition with you – it’s the first clean-label, plant-based formula for toddlers. Romeo and I are making their Complete Nutrition Drink which helps support his growth and development during this key time. Else is organic and non-GMO. It’s FDA-compliant, dairy, soy, and hormone-free. There are no antibiotics, palm oil, or corn syrups that are traditionally found in infant and toddler formulas and milks, so your babies can get the nutrition nature intended! I highly recommend this amazing alternative, especially if you’re like me where you’ve been looking for something Else!”
Posted by AGORACOM-JC
at 6:58 AM on Wednesday, September 2nd, 2020
Wholly owned subsidiary Askott Entertainment has signed a partnership agreement with Las Vegas based GameCo LLC, a pioneer in skill based iGaming products
The partnership will introduce Askott Entertainments esports iGaming platform, Chameleon, to the US regulated market
GameCo holds gaming licenses in almost thirty jurisdictions including, New Jersey and Nevada in the United States
Askott Entertainment will leverage this US license infrastructure by enabling GameCo to become an official reseller of the Chameleon esports betting platform to new and existing partners which will include U.S based casino operators
The partnership agreement will give the combined group an early mover advantage in the U.S. esports iGaming market
Vancouver, British Columbia–(September 2, 2020) – FansUnite Entertainment Inc. (CSE: FANS) (OTC Pink: FUNFF) (“FansUnite” or the “Company”), a technology company providing leading online gaming solutions, is pleased to announce that its wholly owned subsidiary Askott Entertainment has signed a partnership agreement with Las Vegas based GameCo LLC, a pioneer in skill based iGaming products (“GameCo”). The partnership will introduce Askott Entertainments esports iGaming platform, Chameleon, to the US regulated market.
GameCo holds gaming licenses in almost thirty jurisdictions including, New Jersey and Nevada in the United States. Askott Entertainment will leverage this US license infrastructure by enabling GameCo to become an official reseller of the Chameleon esports betting platform to new and existing partners which will include U.S based casino operators. The partnership agreement will give the combined group an early mover advantage in the U.S. esports iGaming market. As the U.S. is one the most desirable and active gambling markets globally, having a presence in that jurisdiction is an integral part of the FansUnite strategy.
“With this newly launched partnership, we are able to showcase our turn-key white label iGaming solution while officially launching our technology into the burgeoning U.S. gaming market,” said Scott Burton, CEO of FansUnite Entertainment. “We are aware of the sizable market that the U.S. presents, and understand that esports is a key component to any traditional sportsbooks future betting offering. This partnership with GameCo is a significant inflection point for FansUnite and accelerates our plans to enter the US market by at least 6-12 months.”
“GameCo was born from the founders’ involvement in the esports industry and invented the category of skill-based Video Game Gambling™. We intend to carry our market leadership position in the U.S. regulated market and provide the industry’s leading turkey, outsourced solution for casinos and sportsbooks to offer esports betting,” said Blaine Graboyes, Co-Founder and CEO of GameCo. “Skill-based games and esports betting are one of the few growth opportunities in the U.S. and we believe Askott provides the most capable and innovative platform for offering iGaming and esports betting.”
With the repeal of PASPA in 2018 any state is now allowed to legalize sports betting. Since that time more than $20 billion has been bet with U.S. sportsbooks1.
About GameCo
GameCo LLC is the foremost innovator and trailblazer in creating new, differentiated gaming products and experiences which are driving the growth in the digital and retail regulated casino industries. The inventor of the world’s first skill-based Video Game Gambling Machine (VGM™), GameCo’s omnichannel land-based and online platform combines the fun and interactivity of video games with the thrill and anticipation of gambling. The company’s patent-pending GamersEdge™ technology allows a player’s skill and strategy to impact the payout and winnings, while maintaining similar economics for the casino as traditional slots. Through its Video Game Gambling™ platform and gaming licenses in dozens of jurisdictions, GameCo enables game developers and publishers to distribute and monetize video games into the licensed gaming market and enables operators to attract and engage new, different customers. GameCo offers a wide portfolio of casino, sports, and core game genres in both single player and esports-style multiplayer formats for retail casinos, and through the iGameCo brand, for digital casinos with iGaming, and esports betting.
GameCo LLC is privately held and headquartered in Las Vegas with additional offices in New York City. GameCo is currently licensed to operate in more than twenty gaming jurisdictions, including Nevada.
About FansUnite Entertainment Inc.
FansUnite is a global sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one of a kind complete iGaming platform, Chameleon Gaming Platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high-growth potential in new or developing markets.
For further information, please contact:
Prit Singh Investor Relations at FansUnite [email protected] (905) 510-7636
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or similar expressions to be uncertain and forward-looking. Forward-looking statements may include, without limitation, statements relating to future outlook and anticipated events such as: the leveraging of GameCo’s US license infrastructure; GameCo becoming an official reseller of the platform; the Company’s entrance into the US market and the Company’s strategy with respect thereto; the importance of the US market to the Company; impacts of the GameCo/Askott partnership on the Company’s success; the Company’s ability to become a leading technology platform and a leader in the global I-gaming market, and to serve the gaming market; the potential growth of the Company and the gaming market; the increased number of betting options; the ability of the Company to scale its B2B arm and maintain its B2C platforms; the Company’s unique portfolio of assets; and discussion of future plans, projections, objectives, estimates and forecasts and the timing related thereto. Forward-looking statements are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of FansUnite to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Additional information regarding the risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Non-Offering Prospectus dated March 27, 2020 filed on its issuer profile on SEDAR at www.sedar.com and risks related to global pandemics, including the novel coronavirus (COVID-19) global health pandemic, and the spread of other viruses or pathogens and influence of macroeconomic developments. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The forward-looking statements in this news release are made as of the date of this release. FansUnite disclaims and does not undertake to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
Posted by AGORACOM-JC
at 6:28 PM on Tuesday, September 1st, 2020
Hollister Biosciences (HOLL:CSE). is a multi-state operator with multiple, high-quality products that are now carried in 230 of California’s 600 dispensaries, where it also claims California’s #1 hash infused pre-roll “HashBone” + another 80 Arizona dispensaries with some of the best concentrate in the State.
But given the state of disappointment in the Cannabis industry over the last 15 months, none of that would mean anything without actual results shareholders and the industry could celebrate. In that regard, Hollister does not disappoint with Q2 numbers coming in as follows:
RECORD REVENUE of $US 8.47M, compared to $200,000 last year and representing an increase of 4,170%
NET INCOME of $300,000, compared to a loss of $2.1M, representing a turnaround of $2.4M over last year
There isn’t a small cap cannabis company that would not cheer for these results – if that was all they had. These numbers are a company maker. But Hollister is set to continue growing on several fronts, including a Direct To Consumer model and further big expansion in California.
Watch this incredible interview with President Alex Somjen.
